{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T08:33:18Z","timestamp":1790929998114,"version":"4.1.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2006,1,1]],"date-time":"2006-01-01T00:00:00Z","timestamp":1136073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neuroscience"],"published-print":{"date-parts":[[2006,1]]},"DOI":"10.1016\/j.neuroscience.2006.05.006","type":"journal-article","created":{"date-parts":[[2006,6,16]],"date-time":"2006-06-16T08:06:08Z","timestamp":1150445168000},"page":"1481-1488","source":"Crossref","is-referenced-by-count":13,"title":["Effects of the vasopressin (V1B) receptor antagonist, SSR149415, and the corticotropin-releasing factor 1 receptor antagonist, SSR125543, on FG 7142-induced increase in acetylcholine and norepinephrine release in the rat"],"prefix":"10.1016","volume":"141","author":[{"given":"Y.","family":"Claustre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Rouquier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Desvignes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Leonetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Mont\u00e9gut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Aubin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Allouard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Bougault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Oury-Donat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Steinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuroscience.2006.05.006_bib1","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/sj.mp.4001464","article-title":"Blockade of CRF(1) or V(1b) receptors reverses stress-induced suppression of neurogenesis in a mouse model of depression","volume":"9","author":"Alonso","year":"2004","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.neuroscience.2006.05.006_bib2","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S1043-2760(00)00304-0","article-title":"Vasopressin receptors","volume":"11","author":"Birnbaumer","year":"2000","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.neuroscience.2006.05.006_bib3","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1111\/j.1471-4159.1991.tb01987.x","article-title":"The anxiogenic beta-carboline FG 7142 selectively increases dopamine release in rat prefrontal cortex as measured by microdialysis","volume":"56","author":"Bradberry","year":"1991","journal-title":"J Neurochem"},{"key":"10.1016\/j.neuroscience.2006.05.006_bib4","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ejphar.2003.11.032","article-title":"Anxiolytic- and antidepressant-like profile of a new CRF1 receptor antagonist, R278995\/CRA0450","volume":"485","author":"Chaki","year":"2004","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.neuroscience.2006.05.006_bib5","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1046\/j.1471-4159.1994.63062086.x","article-title":"Dopaminergic regulation of septohippocampal cholinergic neurons","volume":"63","author":"Day","year":"1994","journal-title":"J Neurochem"},{"key":"10.1016\/j.neuroscience.2006.05.006_bib6","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1046\/j.1471-4159.1998.71020622.x","article-title":"Corticotropin-releasing factor administered centrally, but not peripherally, stimulates hippocampal acetylcholine release","volume":"71","author":"Day","year":"1998","journal-title":"J Neurochem"},{"key":"10.1016\/j.neuroscience.2006.05.006_bib7","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/syn.10024","article-title":"Chronic treatment with imipramine or mirtazapine antagonizes stress- and FG7142-induced increase in cortical norepinephrine output in freely moving rats","volume":"43","author":"Dazzi","year":"2002","journal-title":"Synapse"},{"key":"10.1016\/j.neuroscience.2006.05.006_bib8","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1177\/026988110201600202","article-title":"Inhibition by venlafaxine of the increase in norepinephrine output in rat prefrontal cortex elicited by acute stress or by the anxiogenic drug FG 7142","volume":"16","author":"Dazzi","year":"2002","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.neuroscience.2006.05.006_bib9","first-page":"241","article-title":"Modulation of basal and stress-induced release of acetylcholine and dopamine in rat brain by abecarnil and imidazenil, two anxioselective gamma-aminobutyric acid A receptor modulators","volume":"273","author":"Dazzi","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.neuroscience.2006.05.006_bib10","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/0006-8993(95)01478-0","article-title":"Inhibition by the neurosteroid allopregnanolone of basal and stress-induced acetylcholine release in the brain of freely moving rats","volume":"710","author":"Dazzi","year":"1996","journal-title":"Brain Res"},{"key":"10.1016\/j.neuroscience.2006.05.006_bib11","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0014-2999(03)02130-7","article-title":"Antagonism of the stress-induced increase in cortical norepinephrine output by the selective norepinephrine reuptake inhibitor reboxetine","volume":"476","author":"Dazzi","year":"2003","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.neuroscience.2006.05.006_bib12","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0028-3908(01)00064-8","article-title":"Long-term treatment with antidepressant drugs reduces the sensitivity of cortical cholinergic neurons to the activating actions of stress and the anxiogenic drug FG 7142","volume":"41","author":"Dazzi","year":"2001","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuroscience.2006.05.006_bib13","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/sj.npp.1300624","article-title":"Fluoxetine disrupts the integration of anxiety and aversive memories","volume":"30","author":"Degroot","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuroscience.2006.05.006_bib14","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/sj.npp.1300002","article-title":"Anxious-retarded depression","volume":"28","author":"de Winter","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuroscience.2006.05.006_bib15","doi-asserted-by":"crossref","first-page":"6370","DOI":"10.1073\/pnas.092012099","article-title":"Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders","volume":"99","author":"Griebel","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.neuroscience.2006.05.006_bib16","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1124\/jpet.301.1.333","volume":"301","author":"Griebel","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.neuroscience.2006.05.006_bib17","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2174\/1568007033482850","article-title":"The vasopressin V1b receptor as a therapeutic target in stress-related disorders","volume":"2","author":"Griebel","year":"2003","journal-title":"Curr Drug Targets CNS Neurol Disord"},{"key":"10.1016\/j.neuroscience.2006.05.006_bib18","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1124\/jpet.301.1.322","volume":"301","author":"Gully","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.neuroscience.2006.05.006_bib19","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0022-3956(98)90056-5","article-title":"The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety","volume":"33","author":"Holsboer","year":"1999","journal-title":"J Psychiatr Res"},{"key":"10.1016\/j.neuroscience.2006.05.006_bib20","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/0091-3057(91)90166-Y","article-title":"Anxiogenic beta-carboline FG 7142 produces activation of noradrenergic neurons in specific brain regions of rats","volume":"39","author":"Ida","year":"1991","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.neuroscience.2006.05.006_bib21","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/0014-2999(93)90518-M","article-title":"Inhibition of hippocampal acetylcholine release by benzodiazepines","volume":"238","author":"Imperato","year":"1993","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.neuroscience.2006.05.006_bib22","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/0014-2999(94)90320-4","article-title":"Differential effects of abecarnil on basal release of acetylcholine and dopamine in the rat brain","volume":"261","author":"Imperato","year":"1994","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.neuroscience.2006.05.006_bib23","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/0306-4522(94)00578-S","article-title":"Increases in hippocampal and frontal cortical acetylcholine release associated with presentation of sensory stimuli","volume":"66","author":"Inglis","year":"1995","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuroscience.2006.05.006_bib24","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0014-2999(03)01383-9","article-title":"The CRF1 receptor antagonist, DMP695, abolishes activation of locus coeruleus noradrenergic neurones by CRF in anesthetized rats","volume":"464","author":"Lejeune","year":"2003","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.neuroscience.2006.05.006_bib25","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1124\/jpet.103.058784","volume":"309","author":"Lelas","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.neuroscience.2006.05.006_bib26","doi-asserted-by":"crossref","unstructured":"Louis C, Cohen C, Depoort\u00e8re R, Griebel G (2006) Antidepressant-like effects of the corticotropin-releasing factor 1 receptor antagonist, SSR125543, and the vasopressin V1b receptor antagonist, SSR149415, in a DRL-72s schedule in the rat. Neuropsychopharmacology, in press.","DOI":"10.1038\/sj.npp.1301036"},{"key":"10.1016\/j.neuroscience.2006.05.006_bib27","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/BF02245888","article-title":"Anxiogenic drugs beta-CCE and FG 7142 increase extracellular dopamine levels in nucleus accumbens","volume":"109","author":"McCullough","year":"1992","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuroscience.2006.05.006_bib28","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/0304-3940(95)11444-2","article-title":"Bidirectional modulation of cortical acetylcholine efflux by infusion of benzodiazepine receptor ligands into the basal forebrain","volume":"189","author":"Moore","year":"1995","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.neuroscience.2006.05.006_bib29","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1002\/syn.890210407","article-title":"Stimulation of cortical acetylcholine efflux by FG 7142 measured with repeated microdialysis sampling","volume":"21","author":"Moore","year":"1995","journal-title":"Synapse"},{"key":"10.1016\/j.neuroscience.2006.05.006_bib30","series-title":"The rat brain in stereotaxic coordinates","author":"Paxinos","year":"1998"},{"key":"10.1016\/j.neuroscience.2006.05.006_bib31","series-title":"Neurochemical and behavioural characterization of a vasopressin V3 (V1b) receptor antagonist","author":"Ring","year":"2004"},{"key":"10.1016\/j.neuroscience.2006.05.006_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s002130100756","article-title":"Psychotogenic properties of benzodiazepine receptor inverse agonists","volume":"156","author":"Sarter","year":"2001","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuroscience.2006.05.006_bib33","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1124\/jpet.300.3.1122","article-title":"Characterization of (2S,4R)-1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidine carboxamide (SSR149415), a selective and orally active vasopressin V1b receptor antagonist","volume":"300","author":"Serradeil-Le Gal","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.neuroscience.2006.05.006_bib34","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1046\/j.1460-9568.1998.00244.x","article-title":"Expression and presence of septal neurokinin-2 receptors controlling hippocampal acetylcholine release during sensory stimulation in rat","volume":"10","author":"Steinberg","year":"1998","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.neuroscience.2006.05.006_bib35","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1046\/j.1471-4159.1995.65062543.x","article-title":"Pharmacological characterization of tachykinin receptors controlling acetylcholine release from rat striatum","volume":"65","author":"Steinberg","year":"1995","journal-title":"J Neurochem"},{"key":"10.1016\/j.neuroscience.2006.05.006_bib36","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S0893-133X(97)00054-7","article-title":"Plasma levels of arginine vasopressin elevated in patients with major depression","volume":"17","author":"van Londen","year":"1997","journal-title":"Neuropsychopharmacology"}],"container-title":["Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306452206006622?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306452206006622?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,15]],"date-time":"2019-01-15T11:55:57Z","timestamp":1547553357000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306452206006622"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,1]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006,1]]}},"alternative-id":["S0306452206006622"],"URL":"https:\/\/doi.org\/10.1016\/j.neuroscience.2006.05.006","relation":{},"ISSN":["0306-4522"],"issn-type":[{"value":"0306-4522","type":"print"}],"subject":[],"published":{"date-parts":[[2006,1]]}}}